| 35.32 -0.26 (-0.73%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 46.67 | 1-year : | 54.51 |
| Resists | First : | 39.95 | Second : | 46.67 |
| Pivot price | 32.82 |
|||
| Supports | First : | 33.87 | Second : | 30.12 |
| MAs | MA(5) : | 35.47 |
MA(20) : | 33.03 |
| MA(100) : | 29.36 |
MA(250) : | 21.35 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 59.3 |
D(3) : | 62.3 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 39.95 | Low : | 12.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EWTX ] has closed below upper band by 24.3%. Bollinger Bands are 98.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 36.29 - 36.51 | 36.51 - 36.67 |
| Low: | 34.16 - 34.44 | 34.44 - 34.65 |
| Close: | 34.94 - 35.37 | 35.37 - 35.68 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Thu, 07 May 2026
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story? - Yahoo Finance
Thu, 07 May 2026
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q1 Net Loss $0.46 a Share, vs. FactSet Est of $0.49 Net Loss a Share - marketscreener.com
Thu, 07 May 2026
Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten - ChartMill
Thu, 07 May 2026
Edgewise Therapeutics (NASDAQ: EWTX) posts Q1 2026 net loss of $49M - Stock Titan
Thu, 07 May 2026
Edgewise Therapeutics 1Q 2026: Net income $(49.0M), EPS $(0.46) — 10-Q Summary - TradingView
Thu, 07 May 2026
Edgewise Therapeutics (NASDAQ: EWTX) reports Q1 2026 loss, $499.6M cash - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 108 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 115.8 (%) |
| Shares Short | 10,080 (K) |
| Shares Short P.Month | 9,480 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -34.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -144 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -21.67 |
| PEG Ratio | 0 |
| Price to Book value | 7.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -26.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|